美国囤积瑞德西韦：世界应如何应对？
USA stockpiling of remdesivir: How should the world respond?
机构信息
Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Global Health Policy & Center for Global Development, London, UK.
出版信息
J Comp Eff Res. 2020 Dec;9(18):1243-1246. doi: 10.2217/cer-2020-0174. Epub 2020 Dec 4.
Abstract
The race to find an effective treatment for coronavirus disease 2019 (COVID-19) is still on, with only two treatment options currently authorized for emergency use and/or recommended for patients hospitalized with severe respiratory symptoms: low-dose dexamethasone and remdesivir. The USA decision to stockpile the latter has resulted in widespread condemnation and in similar action being taken by some other countries. In this commentary we discuss whether stockpiling remdesivir is justified in light of the currently available evidence.
摘要
寻找针对 2019 冠状病毒病（COVID-19）的有效治疗方法的竞赛仍在继续，目前仅有两种治疗方案获得紧急使用授权和/或推荐给患有严重呼吸道症状的住院患者使用：低剂量地塞米松和瑞德西韦。美国决定储备瑞德西韦，这招致了广泛的谴责，一些其他国家也采取了类似行动。在本评论中，我们根据现有证据讨论了储备瑞德西韦是否合理。
相似文献
1
USA stockpiling of remdesivir: How should the world respond?美国囤积瑞德西韦：世界应如何应对？
J Comp Eff Res. 2020 Dec;9(18):1243-1246. doi: 10.2217/cer-2020-0174. Epub 2020 Dec 4.
2
Use of remdesivir for patients with Covid-19: a review article.瑞德西韦用于新型冠状病毒肺炎患者：一篇综述文章。
Rev Assoc Med Bras (1992). 2020 Jun;66(6):838-841. doi: 10.1590/1806-9282.66.6.838. Epub 2020 Jul 20.
3
Remdesivir (Veklury) for the Treatment of COVID-19 in Hospitalized Patients.瑞德西韦（Veklury）用于治疗住院的 COVID-19 患者。
Am Fam Physician. 2021 Sep 1;104(3):311-312.
4
Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process.瑞德西韦的紧急使用授权：透明分配流程的必要性。
JAMA. 2020 Jun 16;323(23):2365-2366. doi: 10.1001/jama.2020.8863.
5
Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.联合使用甲基强的松龙和瑞德西韦对 SARS-CoV-2 感染仓鼠模型的有益作用。
Emerg Microbes Infect. 2021 Dec;10(1):291-304. doi: 10.1080/22221751.2021.1885998.
6
COVID-19 updates: Remdesivir (Veklury) in high-risk outpatients with COVID-19.2019冠状病毒病最新情况：瑞德西韦（Veklury）用于高危2019冠状病毒病门诊患者。
Med Lett Drugs Ther. 2022 Feb 21;64(1644):31-32.
7
Remdesivir as a broad-spectrum antiviral drug against COVID-19.瑞德西韦作为一种广谱抗 COVID-19 病毒药物。
Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):541-548. doi: 10.26355/eurrev_202101_24426.
8
Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States : A Retrospective Cohort Study.羟氯喹、瑞德西韦和地塞米松在美国 COVID-19 住院成人患者中的使用：一项回顾性队列研究。
Ann Intern Med. 2021 Oct;174(10):1395-1403. doi: 10.7326/M21-0857. Epub 2021 Aug 17.
9
Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19.瑞德西韦用于治疗COVID-19的孤儿药指定的政策影响
JAMA Intern Med. 2020 Oct 1;180(10):1273-1274. doi: 10.1001/jamainternmed.2020.2759.
10
Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.治疗 SARS-CoV-2 感染的困境：法匹拉韦与瑞德西韦。
Biomed Pharmacother. 2022 Mar;147:112700. doi: 10.1016/j.biopha.2022.112700. Epub 2022 Feb 4.
引用本文的文献
1
Drug stockpiling behavior and its impact on anxiety among the general public in the early stage after the lifting of China's Zero-COVID policy: results from a web-based survey.中国新冠疫情防控政策放开初期公众的囤药行为及其对焦虑情绪的影响：一项基于网络调查的结果
Front Pharmacol. 2025 May 12;16:1524068. doi: 10.3389/fphar.2025.1524068. eCollection 2025.
2
Health technology assessment of tests for SARS-CoV-2 and treatments for COVID-19: A proposed approach and best-practice recommendations.SARS-CoV-2 检测和 COVID-19 治疗的卫生技术评估：拟议方法和最佳实践建议。
Int J Technol Assess Health Care. 2023 Apr 24;39(1):e24. doi: 10.1017/S0266462323000223.
本文引用的文献
1
Drug treatments for covid-19: living systematic review and network meta-analysis.Covid-19 的药物治疗：系统评价和网络荟萃分析。
BMJ. 2020 Jul 30;370:m2980. doi: 10.1136/bmj.m2980.
2
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
3
US purchases world stocks of remdesivir: why the rest of the world should be glad to be at the back of the queue.
BMJ. 2020 Jul 13;370:m2797. doi: 10.1136/bmj.m2797.
4
Drug-induced Liver Injury in a Patient With Coronavirus Disease 2019: Potential Interaction of Remdesivir With P-Glycoprotein Inhibitors.新型冠状病毒疾病 2019 患者的药物性肝损伤：瑞德西韦与 P-糖蛋白抑制剂的潜在相互作用。
Clin Infect Dis. 2021 Apr 8;72(7):1256-1258. doi: 10.1093/cid/ciaa883.
5
Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19.瑞德西韦：对其发现与研发历程的综述，该历程促成了其用于治疗新冠病毒病的紧急使用授权
ACS Cent Sci. 2020 May 27;6(5):672-683. doi: 10.1021/acscentsci.0c00489. Epub 2020 May 4.
6
Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review.重新利用氯喹和羟氯喹作为抗病毒药物的临床证据：系统评价。
Clin Microbiol Infect. 2020 Aug;26(8):979-987. doi: 10.1016/j.cmi.2020.05.016. Epub 2020 May 26.
7
Remdesivir for the Treatment of Covid-19 - Final Report.瑞德西韦治疗 COVID-19 的疗效 - 最终报告。
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
8
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.瑞德西韦治疗成人重症 COVID-19 的随机、双盲、安慰剂对照、多中心临床试验。
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.
9
Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review.单独隔离或与其他公共卫生措施相结合以控制新冠病毒病：一项快速综述
Cochrane Database Syst Rev. 2020 Apr 8;4(4):CD013574. doi: 10.1002/14651858.CD013574.
10
Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy.意大利新冠肺炎死亡患者的病死率及特征
JAMA. 2020 May 12;323(18):1775-1776. doi: 10.1001/jama.2020.4683.
Zotero 插件